Top

Published in:

Open Access 01-06-2012 | Original Article

Outcomes and general health-related quality of life among patients medically treated in general daily practice for lower urinary tract symptoms due to benign prostatic hyperplasia

Authors: Richard-Olivier Fourcade, François Lacoin, Morgan Rouprêt, Alain Slama, Camille Le Fur, Emilie Michel, Axel Sitbon, François-Emery Cotté

Published in: World Journal of Urology | Issue 3/2012

Abstract

Objective

This study’s aim was to describe and evaluate outcomes of medical strategies used for lower urinary tract symptoms (LUTS) treatment in general practice and to assess impact of LUTS on patients’ general health-related quality of life (HRQoL).

Methods

This cross-sectional observational study was conducted by French general practitioners. Eligible patients were males aged ≥50 years, diagnosed for at least one year and currently treated for LUTS due to benign prostatic hyperplasia (BPH). Several validated questionnaires were documented by patients to assess severity of LUTS (IPSS), specific quality of life (IPSS-Q8), impact of LUTS (BII), LUTS evolution (VNS) and general HRQoL (EQ-5D).

Results

Among 1,098 patients included, 82.7% were treated with monotherapies and 17.3% with combinations. Mean treatment duration was 5.2 ± 3.2 years, and 47.2% of patients had at least one treatment modification since initiation. Patients reported diminished quality of life (IPSS-Q8 ≥3) (42.3%), persisting symptoms (IPSS-score ≥12) (35.5%), symptoms worsening (VNS-score ≤−1) (18.8%) and high bother (BII-score ≥9) (2.6%). Globally, 52.8% had at least one of these unsatisfactory outcomes. Regarding general HRQoL, mean EQ-5D utility significantly decreased with LUTS severity (mild: 0.90 ± 0.12; moderate: 0.81 ± 0.21; and severe symptoms: 0.73 ± 0.25; P < 0.001). As well, all five-dimensions of EQ-5D were significantly altered in patients with moderate-to-severe LUTS (<0.001), especially ‘Pain/Discomfort’ and ‘Anxiety/Depression’. In multivariate analyses including age and comorbidities, EQ-5D utility index remained negatively associated with each additional unit in the IPSS-score.

Conclusions

This study shows that around half of BPH patients medically treated report unsatisfactory outcomes, suggesting consequential unmet medical needs in general practice. Also, moderate-to-severe LUTS significantly impact on general HRQoL.

Robert G, Descazeaud A, Azzouzi R, Saussine C, Haillot O, Dumonceau O et al (2010) Impact of lower urinary tract symptoms on discomfort in men aged between 50 and 80 years. Urol Int 84(4):424–429PubMedCrossRef

Desgrandchamps F, de la Taille A, Azzouzi A, Fourmarier M, Haillot O, Lukacs B et al (2006) Management of non-complicated BPH: proposition of a renewed decision tree. World J Urol 24(4):367–370PubMedCrossRef

McVary KT, Roehrborn CG, Avins AL, Barry MJ, Bruskewitz RC, Donnell RF, Foster HE Jr, Gonzalez CM, Kaplan SA, Penson DF, Ulchaker JC, Wei JT (2011) Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol 185(5):1793–1803PubMedCrossRef

Fourcade RO, Théret N, Taïeb C (2008) Profile and management of patients treated for the first time for lower urinary tract symptoms/benign prostatic hyperplasia in four European countries. BJU Int 101(9):1111–1118PubMedCrossRef

Barry MJ, Fowler FJ, O’Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK (1995) Measuring disease-specific health status in men with benign prostatic hyperplasia. Measurement committee of the american urological association. Med Care 33(4 Suppl):145–155

Madersbacher S, Alivizatos G, Nordling J, Sanz CR, Emberton M, de la Rosette JJ (2004) EAU 2004 guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPH guidelines). Eur Urol 46(5):547–554PubMedCrossRef

Fine SR, Ginsberg P (2008) Alpha-adrenergic receptor antagonists in older patients with benign prostatic hyperplasia: issues and potential complications. J Am Osteopath Assoc 108(7):333–337PubMed

Hong SJ, Rayford W, Valiquette L, Emberton M (2005) The importance of patient perception in the clinical assessment of benign prostatic hyperplasia and its management. BJU Int 95(1):15–19PubMedCrossRef

Tanguay S, Awde M, Brock G, Casey R, Kozak J, Lee J et al (2009) Diagnosis and management of benign prostatic hyperplasia in primary care. Can Urol Assoc J 3(3 Suppl):92–100

10.

Jouanneau L, Aout M, Hodé C, Moysan V, Fournier A, Merlière Y, Vicault E, Lukacs B (2008) Observa-Pur. Analyse des prescriptions médicamenteuses pour HBP en France en 2004. Prog Urol 18:707CrossRef

11.

Cotté FE, Fardellone P, Mercier F, Gaudin AF, Roux C (2010) Adherence to monthly and weekly oral bisphosphonates in women with osteoporosis. Osteoporos Int 21(1):145–155PubMedCrossRef

12.

Barry MJ, Fowler FJ, O’Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK et al (1992) The American urological association symptom index for benign prostatic hyperplasia. The measurement committee of the American urological association. J Urol 148(5):1549–1557PubMed

13.

Chevalier J, De Pourville G et al. (2009) Valuing EQ-5D using time trade-off in France. In: Proceedings of the 26th plenary meeting of the EuroQol Group. Paris, France

14.

Roehrborn CG, Siami P, Barkin J, Damião R, Major-Walker K, Nandy I et al (2010) The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol 57(1):123–131PubMedCrossRef

15.

Roehrborn CG, Siami P, Barkin J, Damião R, Major-Walker K, Morrill B et al (2008) The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study. J Urol 179(2):616–621PubMedCrossRef

16.

McConnell JD, Roehrborn CG, Bautista OM, Andriole GL, Dixon CM, Kusek JW et al (2003) The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 349(25):2387–2398PubMedCrossRef

17.

Black L, Grove A, Morrill B (2009) The psychometric validation of a US English satisfaction measure for patients with benign prostatic hyperplasia and lower urinary tract symptoms. Health Qual Life Outcomes 7:55PubMedCrossRef

18.

Madersbacher S, Alivizatos G, Nordling J, Sanz CR, Emberton M, de la Rosette JJMCH (2004) EAU 2004 guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPH guidelines). Eur Urol 46(5):547–554PubMedCrossRef

19.

Nickel JC, Méndez-Probst CE, Whelan TF, Paterson RF, Razvi H (2010) 2010 Update: guidelines for the management of benign prostatic hyperplasia. Can Urol Assoc J 4(5):310–316PubMedCrossRef

20.

Fourcade RO, Picot M, Gaudin AF, Texier N, Slama A (2007) Factors determining treatment strategies for patients with benign prostatic hyperplasia. The DUO study. Press Med 36(5 Suppl):755–763CrossRef

21.

Nickel JC (2006) The economics of medical therapy for lower urinary tract symptoms associated with benign prostatic hyperplasia. Curr Urol Rep 7(4):282–287PubMedCrossRef

22.

Engstrom G, Henningsohn L, Walker-Engstrom ML, Leppert J (2006) Impact on quality of life of different lower urinary tract symptoms in men measured by means of the SF 36 questionnaire. Scand J Urol Nephrol 40(6):485–494PubMedCrossRef

23.

Engström G, Walker-Engström ML, Henningsohn L, Lööf L, Leppert J (2004) Prevalence of distress and symptom severity from the lower urinary tract in men: a population-based study with the DAN-PSS questionnaire. Fam Pract 21(6):617–622PubMedCrossRef

24.

Engström G, Henningsohn L, Steineck G, Leppert J (2005) Self-assessed health, sadness and happiness in relation to the total burden of symptoms from the lower urinary tract. BJU Int 95(6):810–815PubMedCrossRef

25.

Coyne KS, Wein AJ, Tubaro A, Sexton CC, Thompson CL, Kopp ZS, Aiyer LP (2009) The burden of lower urinary tract symptoms: evaluating the effect of LUTS on health-related quality of life, anxiety and depression: EpiLUTS. BJU Int 103(Suppl 3):4–11PubMedCrossRef

26.

Rutten-van Mölken MPMH, Oostenbrink JB, Tashkin DP, Burkhart D, Monz BU (2006) Does quality of life of COPD patients as measured by the generic EuroQol five-dimension questionnaire differentiate between COPD severity stages? Chest 130(4):1117–1128PubMedCrossRef

27.

Vexiau P, Mavros P, Krishnarajah G, Lyu R, Yin D (2008) Hypoglycaemia in patients with type 2 diabetes treated with a combination of metformin and sulphonylurea therapy in France. Diabetes Obes Metab 10(1 Suppl): 16–24

28.

Monz B, Pons ME, Hampel C, Hunskaar S, Quail D, Samsioe G et al (2005) Patient-reported impact of urinary incontinence–results from treatment seeking women in 14 European countries. Maturitas 52(2 Suppl):24–34CrossRef

Title: Outcomes and general health-related quality of life among patients medically treated in general daily practice for lower urinary tract symptoms due to benign prostatic hyperplasia
Authors: Richard-Olivier Fourcade
François Lacoin
Morgan Rouprêt
Alain Slama
Camille Le Fur
Emilie Michel
Axel Sitbon
François-Emery Cotté
Publication date: 01-06-2012
Publisher: Springer-Verlag
Published in: World Journal of Urology / Issue 3/2012
Print ISSN: 0724-4983
Electronic ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-011-0756-2

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Outcomes and general health-related quality of life among patients medically treated in general daily practice for lower urinary tract symptoms due to benign prostatic hyperplasia

Abstract

Objective

Methods

Results

Conclusions

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Objective

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2012

Enhanced urothelial expression of human chorionic gonadotropin beta (hCGβ) in bladder pain syndrome/interstitial cystitis (BPS/IC)

Molecular aspects of prostate cancer

Advances in small molecule inhibitors of androgen receptor for the treatment of advanced prostate cancer

Low testosterone bioavailability is related to prostate cancer diagnose in patients submitted to prostate biopsy

Effect of the heat shock protein HSP27 on androgen receptor expression and function in prostate cancer cells

Videourodynamic changes of botulinum toxin A in patients with neurogenic bladder dysfunction (NBD) and idiopathic detrusor overactivity (IDO) refractory to drug treatment